Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis

Journal of Immunology

Volumn 190, Issue 6, 2013, Pages 2966-2975

  Heuck, Christoph J ^a   Mehta, Jayesh ^b   Bhagat, Tushar ^a   Gundabolu, Krishna ^a   Yu, Yiting ^a   Khan, Shahper ^c   Chrysofakis, Grigoris ^a   Schinke, Carolina ^a   Tariman, Joseph ^b   Vickrey, Eric ^b   Pulliam, Natalie ^b   Nischal, Sangeeta ^a   Zhou, Li ^a   Bhattacharyya, Sanchari ^a   Meagher, Richard ^b   Hu, Caroline ^a   Maqbool, Shahina ^a   Suzuki, Masako ^a   Parekh, Samir ^a   Reu, Frederic ^c   Steidl, Ulrich ^a   Greally, John ^a   Verma, Amit ^a   Singhal, Seema B ^b   more..

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR6; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HEPATOCYTE NUCLEAR FACTOR 6; STAT3 PROTEIN; SYNDECAN 1; TRANSCRIPTION FACTOR EZH2; WNT PROTEIN;

ARTICLE; BINDING SITE; BONE MARROW BIOPSY; CANCER CELL CULTURE; CANCER REGRESSION; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA DAMAGE; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MICROARRAY ANALYSIS; MONOCLONAL IMMUNOGLOBULINEMIA; MYELOMA; MYELOMAGENESIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN MOTIF; RELAPSE; SURVIVAL TIME;

CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; DNA METHYLATION; EARLY DIAGNOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; RECURRENCE; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; SYNDECAN-1; TUMOR CELLS, CULTURED;

EID: 84874856954     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202493     Document Type: Article

References (39)

1. Anguiano, A., S. A. Tuchman, C. Acharya, K. Salter, C. Gasparetto, F. Zhan, M. Dhodapkar, J. Nevins, B. Barlogie, J. D. Shaughnessy, Jr., and A. Potti. 2009. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J. Clin. Oncol. 27: 4197-4203.
2. Zhan, F., Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer, B. Burington, et al. 2006. The molecular classification of multiple myeloma. Blood 108: 2020-2028.
3. Bergsagel, P. L., W. M. Kuehl, F. Zhan, J. Sawyer, B. Barlogie, and J. Shaughnessy, Jr. 2005. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106: 296-303.
4. Zhan, F., B. Barlogie, V. Arzoumanian, Y. Huang, D. R. Williams, K. Hollmig, M. Pineda-Roman, G. Tricot, F. van Rhee, M. Zangari, et al. 2007. Geneexpression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109: 1692-1700.
5. Figueroa, M. E., S. Lugthart, Y. Li, C. Erpelinck-Verschueren, X. Deng, P. J. Christos, E. Schifano, J. Booth, W. van Putten, L. Skrabanek, et al. 2010. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17: 13-27.
6. Alvarez, H., J. Opalinska, L. Zhou, D. Sohal, M. J. Fazzari, Y. Yu, C. Montagna, E. A. Montgomery, M. Canto, K. B. Dunbar, et al. 2011. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet. 7: e1001356.
7. Oda, M., J. L. Glass, R. F. Thompson, Y. Mo, E. N. Olivier, M. E. Figueroa, R. R. Selzer, T. A. Richmond, X. Zhang, L. Dannenberg, et al. 2009. Highresolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Res. 37: 3829-3839.
8. Chapman, M. A., M. S. Lawrence, J. J. Keats, K. Cibulskis, C. Sougnez, A. C. Schinzel, C. L.Harview, J. P. Brunet, G. J. Ahmann,M.Adli, et al. 2011. Initial genome sequencing and analysis of multiple myeloma. Nature 471: 467-472.
9. Khulan, B., R. F. Thompson, K. Ye, M. J. Fazzari, M. Suzuki, E. Stasiek, M. E. Figueroa, J. L. Glass, Q. Chen, C. Montagna, et al. 2006. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res. 16: 1046-1055.
10. Zhou, L., J. Opalinska, D. Sohal, Y. Yu, Y. Mo, T. Bhagat, O. Abdel-Wahab, M. Fazzari, M. Figueroa, C. Alencar, et al. 2011. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J. Biol. Chem. 286: 25211-25223.
11. Thompson, R. F., M. Reimers, B. Khulan, M. Gissot, T. A. Richmond, Q. Chen, X. Zheng, K. Kim, and J. M. Greally. 2008. An analytical pipeline for genomic representations used for cytosine methylation studies. Bioinformatics 24: 1161- 1167.
12. Subramanian, A., P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, and J. P. Mesirov. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102: 15545-15550.
13. Sohal, D., A. Yeatts, K. Ye, A. Pellagatti, L. Zhou, P. Pahanish, Y. Mo, T. Bhagat, J. Mariadason, J. Boultwood, et al. 2008. Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration. PLoS One 3: e2965.
14. Zhou, L., A. N. Nguyen, D. Sohal, J. Ying Ma, P. Pahanish, K. Gundabolu, J. Hayman, A. Chubak, Y. Mo, T. D. Bhagat, et al. 2008. Inhibition of the TGFbeta receptor I kinase promotes hematopoiesis in MDS. Blood 112: 3434-3443.
15. Nair, B., J. D. Shaughnessy, Jr., Y. Zhou, M. Astrid-Cartron, P. Qu, F. van Rhee, E. Anaissie, Y. Alsayed, S. Waheed, K. Hollmig, et al. 2009. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood 113: 6572-6575.
16. Irizarry, R. A., C. Ladd-Acosta, B. Wen, Z. Wu, C. Montano, P. Onyango, H. Cui, K. Gabo, M. Rongione, M. Webster, et al. 2009. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissuespecific CpG island shores. Nat. Genet. 41: 178-186.
17. Ley, T. J., L. Ding, M. J. Walter, M. D. McLellan, T. Lamprecht, D. E. Larson, C. Kandoth, J. E. Payton, J. Baty, J. Welch, et al. 2010. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363: 2424-2433.
18. Walker, B. A., C. P. Wardell, L. Chiecchio, E. M. Smith, K. D. Boyd, A. Neri, F. E. Davies, F. M. Ross, and G. J. Morgan. 2011. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 117: 553-562.
19. Salhia, B., A. Baker, G. Ahmann, D. Auclair, R. Fonseca, and J. Carpten. 2010. DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. Cancer Res. 70: 6934-6944.
20. Figueroa, M. E., O. Abdel-Wahab, C. Lu, P. S. Ward, J. Patel, A. Shih, Y. Li, N. Bhagwat, A. Vasanthakumar, H. F. Fernandez, et al. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.
21. Sharma, A., C. J. Heuck, M. J. Fazzari, J. Mehta, S. Singhal, J. M. Greally, and A. Verma. 2010. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip. Rev. Syst. Biol. Med. 2: 654-669.
22. Cravo, M., R. Pinto, P. Fidalgo, P. Chaves, L. Glória, C. Nobre-Leitao, and F. Costa Mira. 1996. Global DNA hypomethylation occurs in the early stages of intestinal type gastric carcinoma. Gut 39: 434-438.
23. Ehrlich, M. 2002. DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400-5413.
24. Esteller, M. 2003. Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv. Exp. Med. Biol. 532: 39-49.
25. Hardin, J., M. Waddell, C. D. Page, F. Zhan, B. Barlogie, J. Shaughnessy, and J. J. Crowley. 2004. Evaluation of multiple models to distinguish closely related forms of disease using DNA microarray data: an application to multiple myeloma. Stat. Appl. Genet. Mol. Biol. 3: 1-21.
26. Anguiano, A., S. A. Tuchman, C. Acharya, K. Salter, C. Gasparetto, F. Zhan, M. Dhodapkar, J. Nevins, B. Barlogie, J. D. Shaughnessy, Jr., et al. 2009. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J. Clin. Oncol. 27: 4197-4203.
27. Wilop, S., T. B. van Gemmeren, M. H. Lentjes, M. van Engeland, J. G. Herman, T. H. Brummendorf, E. Jost, and O. Galm. 2011. Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma. Epigenetics 6: 1047-1052.
28. Nojima, M., R. Maruyama, H. Yasui, H. Suzuki, Y. Maruyama, I. Tarasawa, Y. Sasaki, H. Asaoku, H. Sakai, T. Hayashi, et al. 2009. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin. Cancer Res. 15: 4356-4364.
29. Jones, P. A., and G. Liang. 2009. Rethinking how DNA methylation patterns are maintained. Nat. Rev. Genet. 10: 805-811.
30. Thol, F., F. Damm, A. Lüdeking, C. Winschel, K. Wagner, M. Morgan, H. Yun, G. Göhring, B. Schlegelberger, D. Hoelzer, et al. 2011. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J. Clin. Oncol. 29: 2889-2896.
31. Kubota, M., Y. W. Lin, K. Hamahata, M. Sawada, S. Koishi, H. Hirota, and Y. Wakazono. 2000. Cancer chemotherapy and somatic cell mutation. Mutat. Res. 470: 93-102.
32. Karp, J. E., and M. A. Smith. 1997. The molecular pathogenesis of treatmentinduced (secondary) leukemias: foundations for treatment and prevention. Semin. Oncol. 24: 103-113.
33. Lewandowska, J., and A. Bartoszek. 2011. DNA methylation in cancer development, diagnosis and therapy - multiple opportunities for genotoxic agents to act as methylome disruptors or remediators. Mutagenesis 26: 475-487.
34. Zeller, C., W. Dai, N. L. Steele, A. Siddiq, A. J. Walley, C. S. Wilhelm-Benartzi, S. Rizzo, A. van der Zee, J. A. Plumb, and R. Brown. 2012. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 31: 4567-4576.
35. Chen, B., X. Rao, M. G. House, K. P. Nephew, K. J. Cullen, and Z. Guo. 2011. GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response. Cancer Lett. 309: 37-45.
36. Cheetham, S., M. J. Tang, F. Mesak, H. Kennecke, D. Owen, and I. T. Tai. 2008. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5- Aza-29deoxycytidine to increase SPARC expression and improve therapy response. Br. J. Cancer 98: 1810-1819.
37. Leshchenko, V., P.-Y. Kuo, N. Ulahannan, E. Braunschweig, Y. Yu, S. Suh, M. Weniger, A. Goy, W. Wymdham, A. Wiestner, et al. 2011. High-resolution sequencing identifies NOXA1 de-methylation as a novel strategy to overcome bortezomib resistance in mantle cell lymphoma. 53rd ASH Annual Meeting and Exposition 2011, Abstract 557.
38. Negrotto, S., K. P. Ng, A. M. Jankowska, J. Bodo, B. Gopalan, K. Guinta, J. C. Mulloy, E. Hsi, J. Maciejewski, and Y. Saunthararajah. 2012. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia 26: 244-254.
39. Tsai, H. C., H. Li, L. Van Neste, Y. Cai, C. Robert, F. V. Rassool, J. J. Shin, K. M. Harbom, R. Beaty, E. Pappou, et al. 2012. Transient low doses of DNAdemethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21: 430-446.